Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
82.4 CHF | 0.00% |
|
+1.98% | +1.98% |
May. 31 | Skan Group Boosts Interest in Belgian Unit Aseptic Technologies to 90% | MT |
Mar. 26 | Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 53.16 and 37.54 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.63 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.98% | 2.07B | - | ||
+75.69% | 12.57B | B- | ||
+8.29% | 6.66B | C- | ||
+15.10% | 5.5B | D+ | ||
-18.30% | 4.88B | B | ||
+14.96% | 4.1B | - | ||
-20.83% | 3.89B | B- | ||
-27.58% | 2.83B | C | ||
+44.07% | 2.31B | C- | ||
+9.75% | 1.97B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SKAN Stock
- Ratings SKAN Group AG